Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional

Safety and Efficacy of Celecoxib Versus Placebo in the Treatment of Knee Osteoarthritis in Patients Who Were Unresponsive to Naproxen and Ibuprofen

ClinicalTrials.gov ID: NCT00638807

Public ClinicalTrials.gov record NCT00638807. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 7:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-Blind, Placebo Controlled Study of the Efficacy and Tolerability of Once Daily Celebrex (Celecoxib) vs. Placebo in the Treatment of Subjects With Osteoarthritis of the Knee Non-Responsive to Naproxen and Ibuprofen

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To compare the efficacy and safety of celecoxib versus placebo for the treatment of knee osteoarthritis (OA) in patients who were unresponsive to prescription strength naproxen and ibuprofen or who could not tolerate prescription strength naproxen and ibuprofen

Study identification

NCT ID
NCT00638807
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Enrollment
388 participants

Conditions and interventions

Interventions

Drug · Other

Eligibility (public fields only)

Age range
40 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2003
Primary completion
Not listed
Completion
Jun 30, 2004
Last update posted
Feb 1, 2021

2003 – 2004

United States locations

U.S. sites
33
U.S. states
23
U.S. cities
31
Facility City State ZIP Site status
Pfizer Investigational Site Birmingham Alabama 35235
Pfizer Investigational Site Buena Park California 90620
Pfizer Investigational Site Denver Colorado 80204
Pfizer Investigational Site Washington D.C. District of Columbia 20006
Pfizer Investigational Site Longwood Florida 32779
Pfizer Investigational Site Miami Florida 33186
Pfizer Investigational Site Zephyrhills Florida 33540
Pfizer Investigational Site Boise Idaho 83704
Pfizer Investigational Site Boise Idaho 83706
Pfizer Investigational Site Morton Grove Illinois 60053
Pfizer Investigational Site Wichita Kansas 67206
Pfizer Investigational Site Wichita Kansas 67214
Pfizer Investigational Site Wheaton Maryland 20902
Pfizer Investigational Site Springfield Missouri 65807
Pfizer Investigational Site Bozeman Montana 59715
Pfizer Investigational Site Trenton New Jersey 08611
Pfizer Investigational Site Binghamton New York 13901
Pfizer Investigational Site Brooklyn New York 11203
Pfizer Investigational Site New York New York 10022-1009
Pfizer Investigational Site Cary North Carolina 27609
Pfizer Investigational Site Winston-Salem North Carolina 27103
Pfizer Investigational Site Bismarck North Dakota 58506
Pfizer Investigational Site Eugene Oregon 97401
Pfizer Investigational Site Portland Oregon 97239
Pfizer Investigational Site Duncansville Pennsylvania 16635-0909
Pfizer Investigational Site Johnstown Pennsylvania 15904
Pfizer Investigational Site Warwick Rhode Island 02886
Pfizer Investigational Site Charleston South Carolina 29407
Pfizer Investigational Site New Tazewell Tennessee 37825
Pfizer Investigational Site San Antonio Texas 78229
Pfizer Investigational Site Arlington Virginia 22203
Pfizer Investigational Site Norfolk Virginia 23502
Pfizer Investigational Site Seattle Washington 98166

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00638807, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 1, 2021 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00638807 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →